Zhen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhen Wang has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Qin
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
19 shared publications - Xiaozheng Kang
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
18 shared publications - Liyan Xue
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
17 shared publications - Qingfeng Zheng
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
17 shared publications - Yin Li
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
17 shared publications - Guojie Feng
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1762797
Urban residents’ health literacy of four major cancers: a cross-sectional national survey
Background: Cancer poses a significant global healthcare challenge, and individual health literacy directly impacts screening and the adoption of self-care behaviors. Objectives: This study aimed to compare health literacy scores for four cancers (colorectal, esophageal, lung, and kidney) among Chinese urban residents and to identify associated factors. Methods: A descriptive cross-sectional study recruited 1,226 urban adults via professional networks across China. Participants provided demographic data and completed a validated health literacy questionnaire. Multiple linear regression was used to analyze associations with health literacy scores. Results: Health literacy scores ranked as follows: colorectal (7.50 ± 3.35), esophageal (6.27 ± 3.15), lung (5.88 ± 3.07), and kidney (4.30 ± 2.89). Education and household income emerged as consistent predictors of health literacy across all cancers. Age, sex, employment status, and a family history of cancer were associated with colorectal cancer health literacy scores. Participants who reported higher levels of health literacy scores in esophageal cancer were older and had a previous cancer diagnosis. Participants who reported higher lung cancer health literacy scores were older, female, retired, and had a family history of cancer. Factors contributing to higher kidney cancer health literacy scores included education, annual household income, and non-smoking status. Conclusion: Urban residents demonstrated moderate levels of cancer-related health literacy, and public health strategies should be targeted toward people with lower education and reduced annual household income. Implication for Practice: This research highlights the need for targeted educational interventions in community healthcare settings to identify urban residents at high risk of low health literacy, ultimately strengthening the reach and impact of cancer screening and prevention programs.
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1762797
Open AccessUrban residents’ health literacy of four major cancers: a cross-sectional national survey
Background: Cancer poses a significant global healthcare challenge, and individual health literacy directly impacts screening and the adoption of self-care behaviors. Objectives: This study aimed to compare health literacy scores for four cancers (colorectal, esophageal, lung, and kidney) among Chinese urban residents and to identify associated factors. Methods: A descriptive cross-sectional study recruited 1,226 urban adults via professional networks across China. Participants provided demographic data and completed a validated health literacy questionnaire. Multiple linear regression was used to analyze associations with health literacy scores. Results: Health literacy scores ranked as follows: colorectal (7.50 ± 3.35), esophageal (6.27 ± 3.15), lung (5.88 ± 3.07), and kidney (4.30 ± 2.89). Education and household income emerged as consistent predictors of health literacy across all cancers. Age, sex, employment status, and a family history of cancer were associated with colorectal cancer health literacy scores. Participants who reported higher levels of health literacy scores in esophageal cancer were older and had a previous cancer diagnosis. Participants who reported higher lung cancer health literacy scores were older, female, retired, and had a family history of cancer. Factors contributing to higher kidney cancer health literacy scores included education, annual household income, and non-smoking status. Conclusion: Urban residents demonstrated moderate levels of cancer-related health literacy, and public health strategies should be targeted toward people with lower education and reduced annual household income. Implication for Practice: This research highlights the need for targeted educational interventions in community healthcare settings to identify urban residents at high risk of low health literacy, ultimately strengthening the reach and impact of cancer screening and prevention programs.
- Open Access
- 13 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10129-10138
Validation and refinement of the AJCC 8th edition ypStage in esophageal squamous cell carcinoma after neoadjuvant therapy: a large-scale retrospective cohort study
Background: The AJCC 8th edition post-neoadjuvant pathologic stage (ypStage) shows limited prognostic discrimination in esophageal squamous cell carcinoma (ESCC). Alternative strategies have been proposed, but most were limited by small samples and lack of inclusion of patients treated with immunotherapy. This study aimed to validate the AJCC 8th edition ypStage and develop a refined ypStage system with improved prognostic performance for ESCC. Methods: This was a large retrospective cohort study including 1848 consecutive ESCC patients treated with neoadjuvant therapy followed by esophagectomy between June 2018 and September 2023. Patients were randomly assigned to training ( n = 1108) and validation ( n = 740) cohorts. A refined ypStage was developed using recursive partitioning analysis (RPA). Survival outcomes were evaluated using Kaplan-Meier curves and log-rank tests, and multivariable Cox proportional hazards regression was used to confirm independent prognostic value. Prognostic performance of the RPA and AJCC 8th edition ypStage systems was compared using the Groome criteria: hazard consistency, hazard discrimination, sample balance, outcome prediction, and overall score. Subgroup analyses were performed by neoadjuvant therapy type. Results: The AJCC 8th edition ypStage showed a reversal of the expected survival hierarchy between ypStage II and IIIA [3-year overall survival (OS): II, 80.1%; IIIA, 90.7%]. RPA identified three groups: ypStage I (ypT0-2N0-1), II (ypT0-2N2-3 or ypT3-4bN0-1), and III (ypT3-4bN2-3). In the validation cohort, RPA ypStage demonstrated clear survival separation (3-year OS: I, 91.2%; II, 79.1%; III, 60.5%; pairwise P < 0.01). Multivariable analysis confirmed its independent prognostic value [II vs I: Hazard Ratio (HR) = 2.44, 95% Confidence Interval (CI): 1.68–3.52; III vs I: HR = 3.67, 95% CI: 2.28–5.90; both P < 0.001]. RPA ypStage outperformed AJCC ypStage across all evaluation metrics. Subgroup analyses further supported its robustness, particularly in patients receiving chemotherapy or chemo-immunotherapy. Conclusion: The RPA-derived ypStage provides improved prognostic stratification compared with the AJCC 8th edition in ESCC patients following neoadjuvant therapy. Further external validation is warranted for potential incorporation into future staging guidelines.
- 13 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10129-10138
Open AccessValidation and refinement of the AJCC 8th edition ypStage in esophageal squamous cell carcinoma after neoadjuvant therapy: a large-scale retrospective cohort study
Background: The AJCC 8th edition post-neoadjuvant pathologic stage (ypStage) shows limited prognostic discrimination in esophageal squamous cell carcinoma (ESCC). Alternative strategies have been proposed, but most were limited by small samples and lack of inclusion of patients treated with immunotherapy. This study aimed to validate the AJCC 8th edition ypStage and develop a refined ypStage system with improved prognostic performance for ESCC. Methods: This was a large retrospective cohort study including 1848 consecutive ESCC patients treated with neoadjuvant therapy followed by esophagectomy between June 2018 and September 2023. Patients were randomly assigned to training ( n = 1108) and validation ( n = 740) cohorts. A refined ypStage was developed using recursive partitioning analysis (RPA). Survival outcomes were evaluated using Kaplan-Meier curves and log-rank tests, and multivariable Cox proportional hazards regression was used to confirm independent prognostic value. Prognostic performance of the RPA and AJCC 8th edition ypStage systems was compared using the Groome criteria: hazard consistency, hazard discrimination, sample balance, outcome prediction, and overall score. Subgroup analyses were performed by neoadjuvant therapy type. Results: The AJCC 8th edition ypStage showed a reversal of the expected survival hierarchy between ypStage II and IIIA [3-year overall survival (OS): II, 80.1%; IIIA, 90.7%]. RPA identified three groups: ypStage I (ypT0-2N0-1), II (ypT0-2N2-3 or ypT3-4bN0-1), and III (ypT3-4bN2-3). In the validation cohort, RPA ypStage demonstrated clear survival separation (3-year OS: I, 91.2%; II, 79.1%; III, 60.5%; pairwise P < 0.01). Multivariable analysis confirmed its independent prognostic value [II vs I: Hazard Ratio (HR) = 2.44, 95% Confidence Interval (CI): 1.68–3.52; III vs I: HR = 3.67, 95% CI: 2.28–5.90; both P < 0.001]. RPA ypStage outperformed AJCC ypStage across all evaluation metrics. Subgroup analyses further supported its robustness, particularly in patients receiving chemotherapy or chemo-immunotherapy. Conclusion: The RPA-derived ypStage provides improved prognostic stratification compared with the AJCC 8th edition in ESCC patients following neoadjuvant therapy. Further external validation is warranted for potential incorporation into future staging guidelines.
- Open Access
- 9 July 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1630231
Comprehensive fragmentation of cell-free repetitive DNA for enhanced cancer detection in plasma
Background: Repetitive elements account for a large proportion of the human genome and undergo alterations during early tumorigenesis. However, the exclusive fragmentation pattern of DNA-derived cell-free repetitive elements (cfREs) remains unclear.Methods: This study enrolled 32 healthy volunteers and 112 patients with five types of cancer. A novel repetitive fragmentomics approach was proposed to profile cfREs using low-pass whole genome sequencing (WGS). Five innovative repetitive fragmentomic features were designed: fragment ratio, fragment length, fragment distribution, fragment complexity, and fragment expansion. A machine learning-based multimodal model was developed using these features.Results: The multimodal model achieved high prediction performance for early tumor detection, even at ultra-low sequencing depths (0.1×, AUC = 0.9824). Alu and short tandem repeat (STR) were identified as the primary cfREs after filtering out low-efficiency subfamilies. Characterization of cfREs within tumor-specific regulatory regions enabled accurate tissue-of-origin (TOO) prediction (0.1×, accuracy = 0.8286) and identified aberrantly transcribed tumor driver genes.Conclusion: This study highlights the abundance of repetitive DNA in plasma. The innovative fragmentomics approach provides a sensitive, robust, and cost-effective method for early tumor detection and localization.
- 9 July 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1630231
Open AccessComprehensive fragmentation of cell-free repetitive DNA for enhanced cancer detection in plasma
Background: Repetitive elements account for a large proportion of the human genome and undergo alterations during early tumorigenesis. However, the exclusive fragmentation pattern of DNA-derived cell-free repetitive elements (cfREs) remains unclear.Methods: This study enrolled 32 healthy volunteers and 112 patients with five types of cancer. A novel repetitive fragmentomics approach was proposed to profile cfREs using low-pass whole genome sequencing (WGS). Five innovative repetitive fragmentomic features were designed: fragment ratio, fragment length, fragment distribution, fragment complexity, and fragment expansion. A machine learning-based multimodal model was developed using these features.Results: The multimodal model achieved high prediction performance for early tumor detection, even at ultra-low sequencing depths (0.1×, AUC = 0.9824). Alu and short tandem repeat (STR) were identified as the primary cfREs after filtering out low-efficiency subfamilies. Characterization of cfREs within tumor-specific regulatory regions enabled accurate tissue-of-origin (TOO) prediction (0.1×, accuracy = 0.8286) and identified aberrantly transcribed tumor driver genes.Conclusion: This study highlights the abundance of repetitive DNA in plasma. The innovative fragmentomics approach provides a sensitive, robust, and cost-effective method for early tumor detection and localization.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 5. Results of univariate analyses for overall survival
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 5. Results of univariate analyses for overall survival
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose:This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC).Patients and Methods:Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate.Results:Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS.Conclusions:Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose:This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC).Patients and Methods:Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate.Results:Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS.Conclusions:Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5061-5072
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5061-5072
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 1. Kaplan-Meier estimates of survival in the R0 resection and non-surgery group
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 1. Kaplan-Meier estimates of survival in the R0 resection and non-surgery group
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 3. Prognostic analysis of esophageal squamous cell carcinoma in MRD status
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 3. Prognostic analysis of esophageal squamous cell carcinoma in MRD status
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 8. Associations of genetic alterations with prognosis.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 8. Associations of genetic alterations with prognosis.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 4. Results of univariate analyses for progression-free survival
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 4. Results of univariate analyses for progression-free survival